publication date: Mar. 31, 2016

Ovarian Cancer

Study: Reolysin-Paclitaxel Combination Demonstrates Higher Response than Paclitaxel Therapy Alone

 

Updated results from a phase II trial of Reolysin and paclitaxel in ovarian cancer patients showed that an intent-to-treat analysis of tumor response, as assessed by CA-125 antigen levels, demonstrated statistically significantly higher full response rates and stable disease or better rates in the test arm compared to paclitaxel alone.

The rate of full responses in the combination arm was 9.26 percent, compared to 1.85 percent in the control arm (p = 0.0196). The rate of stable disease or better in the test arm was 44.44 percent, compared with 24.08 percent in the control arm (p = 0.0096).

Response rates as measured by RECIST were performed on patients with measurable disease (n=68, out of 108 total). The proportion responding on the test arm was 17 percent compared to 20 percent in the control arm.

The study, GOG-0186H, is a randomized clinical trial of paclitaxel versus paclitaxel plus Reolysin in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer. The update follows a presentation of the study at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer. The study was sponsored by the NCI and conducted by the former GOG, now incorporated into NRG Oncology.

An analysis of progression free survival stratified by measurable disease and platinum-free interval (test arm: n=54, 43 progressions, and control arm: n = 54, 48 progressions) was performed and demonstrated a median PFS of 4.4 months … Continue reading CCL March – Study: Reolysin-Paclitaxel Combination Demonstrates Higher Response than Paclitaxel Therapy Alone

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.